# The relationship between long non-coding gene CASC21 polymorphisms and cervical cancer

## TL;DR

This study finds that two genetic variations in the CASC21 gene are linked to a higher risk of cervical cancer.

## Contribution

The study is the first to identify specific CASC21 SNPs associated with cervical cancer risk.

## Key findings

- rs16902094 and rs16902104 SNPs in CASC21 are associated with increased cervical cancer risk.
- The SNPs remained significant in subgroups like older age and non-obese individuals.
- MDR analysis confirmed these SNPs as key contributors to cervical cancer risk.

## Abstract

CASC21 was reported to be a hotspot gene in cervical cancer. The relationship between CASC21 genetic polymorphisms and cervical cancer has not been reported. Genetic factors influence the occurrence of cervical cancer. Thus, we explored the correlation between CASC21 polymorphisms and cervical cancer.

A total of 973 participants within 494 cervical cancer cases and 479 healthy controls were recruited. Five single nucleotide polymorphisms (SNPs) in the CASC21 gene were genotyped using the Agena MassARRAY platform. Chi-squared test, logistic regression analysis, odds ratio (OR), multifactor dimensionality reduction (MDR), and 95% confidence interval (95%CI) were used for data analysis.

In the overall analysis, rs16902094 (p = .014, OR = 1.86, 95% CI = 1.12–3.08) and rs16902104 (p = .014, OR = 1.86, 95% CI = 1.12–3.09) had the risk-increasing correlation with the occurrence of cervical cancer. Stratification analysis showed that rs16902094 and rs16902104 were still associated with cervical cancer risk in the subgroups with age > 51, BMI < 24 kg/m2, smokers, and patients with cervical squamous cell carcinoma. MDR analysis displayed that rs16902094 (.49%) and rs16902104 (.52%) were the main influential attribution factor for cervical cancer risk.

Our finding firstly determined that two CASC21 SNPs (rs16902094, rs16902104) were associated with an increased risk of cervical cancer, which adds to our knowledge regarding the effect of CASC21 on cervical carcinogenesis.